Drug intelligence / Profile preview

Prostate-TAC-CLL01

Development stage: Unknown
Lead developer: ViferaXS
Modality: Peptides

Overview

Prostate-TAC-CLL01 is an "off-the-shelf" peptide-based T-cell activator developed by ViferaXS. It is currently in Phase 1 clinical development for the treatment of prostate cancer. The therapeutic is designed to be used in combination with a BCR (B-cell receptor) bispecific antibody to enhance T-cell mediated anti-tumor activity. As a peptide-based activator, it aims to provide a standardized, readily available immunotherapy option for patients with prostate cancer by stimulating the immune system to recognize and attack malignant cells.

Targets

γδ TCR (T-cell receptor)

Beyond the preview

Go deeper on Prostate-TAC-CLL01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Prostate-TAC-CLL01.

Explore the full profile